DOBUTAMINE 12.5 Mg/Ml Concentrate for Soln for Inf Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

dobutamine 12.5 mg/ml concentrate for soln for inf

claris lifesciences (uk) limited - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml - adrenergic and dopaminergic agents

STERILE DOBUTAMINE HYDROCHLORIDE CONCENTRATE Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

sterile dobutamine hydrochloride concentrate

hospira uk limited - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml - dobutamine

DOBUTAMINE injection, solution Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

dobutamine injection, solution

hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine in 5% dextrose injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine in 5% dextrose injection, usp is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine or any of its components.

DOBUTAMINE injection, solution, concentrate Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

dobutamine injection, solution, concentrate

hainan poly pharm. co., ltd. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine

DOBUTAMINE injection Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

dobutamine injection

slate run pharmaceuticals - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hydrochloride is contraindic

DOBUTAMINE HYDROCHLORIDE injection Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

dobutamine hydrochloride injection

hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine hydrochloride in 5% dextrose injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hydrochloride in 5% dextrose injection is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

DILTIAZEM HYDROCHLORIDE tablet
DILTIAZEM HYDROCHLORIDE tablet Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

diltiazem hydrochloride tablet diltiazem hydrochloride tablet

oceanside pharmaceuticals - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 30 mg - diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. diltiazem hydrochloride tablets are contraindicated in:

PROPRANOLOL HYDROCHLORIDE ER- propranolol hydrochloride capsule, extended release Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

propranolol hydrochloride er- propranolol hydrochloride capsule, extended release

rouses point pharm - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 60 mg - propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. they may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. propranolol hydrochloride extended-release capsules are not indicated in the management of hypertensive emergencies. propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. propranolol hydrochloride extended-release capsules improve nyha functional class in symptomatic patients with hypertrophic subaortic stenosis. propranolol is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block;

PROPRANOLOL HYDROCHLORIDE ER- propranolol hydrochloride capsule, extended release Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

propranolol hydrochloride er- propranolol hydrochloride capsule, extended release

blenheim pharmacal, inc. - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 80 mg - hypertension propranolol hydrochloride extended-release capsules are indicated in the management of hypertension. they may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. propranolol hydrochloride extended-release capsules are not indicated in the management of hypertensive emergencies. angina pectoris due to coronary atherosclerosis propranolol hydrochloride extended-release capsules are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. migraine propranolol hydrochloride extended-release capsules are indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. hypertrophic subaortic stenosis propranolol hydrochloride extended-release capsules improve nyha functional class in symptomatic patients with hypertrophic subaortic stenosis. propranolol